Magle Chemoswed Holding Ab (MAGLE) - Net Assets

Latest as of December 2025: Skr395.84 Million SEK ≈ $42.60 Million USD

Based on the latest financial reports, Magle Chemoswed Holding Ab (MAGLE) has net assets worth Skr395.84 Million SEK (≈ $42.60 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr911.03 Million ≈ $98.04 Million USD) and total liabilities (Skr515.19 Million ≈ $55.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Magle Chemoswed Holding Ab tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr395.84 Million
% of Total Assets 43.45%
Annual Growth Rate 31.99%
5-Year Change 185.21%
10-Year Change N/A
Growth Volatility 87.71

Magle Chemoswed Holding Ab - Net Assets Trend (2017–2025)

This chart illustrates how Magle Chemoswed Holding Ab's net assets have evolved over time, based on quarterly financial data. See how many days can Magle Chemoswed Holding Ab fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Magle Chemoswed Holding Ab (2017–2025)

The table below shows the annual net assets of Magle Chemoswed Holding Ab from 2017 to 2025. For live valuation and market cap data, see market value of Magle Chemoswed Holding Ab.

Year Net Assets Change
2025-12-31 Skr395.84 Million
≈ $42.60 Million
-29.39%
2024-12-31 Skr560.60 Million
≈ $60.33 Million
+254.31%
2023-12-31 Skr158.22 Million
≈ $17.03 Million
+7.81%
2022-12-31 Skr146.77 Million
≈ $15.79 Million
+5.75%
2021-12-31 Skr138.79 Million
≈ $14.94 Million
+19.52%
2020-12-31 Skr116.12 Million
≈ $12.50 Million
+2.17%
2019-12-31 Skr113.66 Million
≈ $12.23 Million
+124.30%
2018-12-31 Skr50.67 Million
≈ $5.45 Million
+17.89%
2017-12-31 Skr42.98 Million
≈ $4.63 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Magle Chemoswed Holding Ab's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock Skr1.03 Million 0.26%
Other Components Skr394.81 Million 99.74%
Total Equity Skr395.84 Million 100.00%

Magle Chemoswed Holding Ab Competitors by Market Cap

The table below lists competitors of Magle Chemoswed Holding Ab ranked by their market capitalization.

Company Market Cap
JEMTEC Inc
V:JTC
$2.22 Million
Webac Holding AG
F:RKB
$2.22 Million
Falcon Oil & Gas Ltd.
LSE:FOG
$2.23 Million
ORIGEN RESOURCES INC. NEW
F:4VXA
$2.23 Million
OCEAN-GEOLOOP AS NK -01
F:FQ4
$2.22 Million
Rakovina Therapeutics Inc
V:RKV
$2.22 Million
Atomic Minerals Corp
V:ATOM
$2.21 Million
Literacy Capital PLC
LSE:BOOK
$2.21 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Magle Chemoswed Holding Ab's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 560,603,000 to 395,844,000, a change of -164,759,000 (-29.4%).
  • Net loss of 159,885,000 reduced equity.
  • Other comprehensive income increased equity by 4,103,000.
  • Other factors decreased equity by 8,977,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr-159.88 Million -40.39%
Other Comprehensive Income Skr4.10 Million +1.04%
Other Changes Skr-8.98 Million -2.27%
Total Change Skr- -29.39%

Book Value vs Market Value Analysis

This analysis compares Magle Chemoswed Holding Ab's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.05x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 Skr8.45 Skr1.00 x
2018-12-31 Skr4.98 Skr1.00 x
2019-12-31 Skr11.18 Skr1.00 x
2020-12-31 Skr15.24 Skr1.00 x
2021-12-31 Skr12.85 Skr1.00 x
2022-12-31 Skr13.59 Skr1.00 x
2023-12-31 Skr14.69 Skr1.00 x
2024-12-31 Skr27.33 Skr1.00 x
2025-12-31 Skr19.17 Skr1.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Magle Chemoswed Holding Ab utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -40.39%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -56.51%
  • • Asset Turnover: 0.31x
  • • Equity Multiplier: 2.30x
  • Recent ROE (-40.39%) is below the historical average (-1.53%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2017 11.74% 4.48% 0.76x 3.44x Skr747.80K
2018 -6.43% -3.08% 0.69x 3.01x Skr-8.33 Million
2019 0.66% 0.59% 0.60x 1.87x Skr-10.62 Million
2020 1.57% 1.28% 0.72x 1.71x Skr-9.79 Million
2021 3.08% 3.24% 0.56x 1.71x Skr-9.60 Million
2022 6.23% 6.28% 0.58x 1.72x Skr-5.53 Million
2023 7.69% 7.14% 0.62x 1.73x Skr-3.65 Million
2024 2.13% 5.06% 0.22x 1.95x Skr-44.12 Million
2025 -40.39% -56.51% 0.31x 2.30x Skr-199.47 Million

Industry Comparison

This section compares Magle Chemoswed Holding Ab's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $159,185,570
  • Average return on equity (ROE) among peers: -26.34%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Magle Chemoswed Holding Ab (MAGLE) Skr395.84 Million 11.74% 1.30x $2.22 Million
2cureX AB (2CUREX) $74.34 Million -25.47% 0.06x $5.16 Million
Ascelia Pharma AB (publ) (ACE) $237.06 Million -16.83% 0.06x $41.03 Million
AcouSort AB (ACOU) $376.48K 28.69% 1.44x $9.52 Million
Active Biotech AB (ACTI) $46.67 Million -106.88% 0.22x $103.60 Million
Alzinova AB (ALZ) $105.53 Million -12.38% 0.06x $8.00 Million
AlzeCure Pharma (ALZCUR) $233.17 Million -15.43% 0.02x $46.62 Million
Annexin Pharmaceuticals AB (ANNX) $15.57 Million -63.12% 0.51x $9.23 Million
Alligator Bioscience AB (ATORX) $41.44 Million 0.00% 0.15x $11.36 Million
BioInvent International AB (BINV) $49.01 Million -36.81% 0.66x $163.58 Million
BioArctic AB (publ) (BIOA-B) $788.68 Million -15.19% 0.14x $2.39 Billion

About Magle Chemoswed Holding Ab

ST:MAGLE Sweden Biotechnology
Market Cap
$2.22 Million
Skr20.65 Million SEK
Market Cap Rank
#29855 Global
#689 in Sweden
Share Price
Skr1.00
Change (1 day)
-2.91%
52-Week Range
Skr1.00 - Skr27.80
All Time High
Skr46.00
About

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride… Read more